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ARTICLE
Clinical Study
Severity of COVID-19 in children with cancer: Report from
the United Kingdom Paediatric Coronavirus Cancer
Monitoring Project
Gerard C. Millen 1,2, Roland Arnold3, Jean-Baptiste Cazier4, Helen Curley3, Richard G. Feltbower5, Ashley Gamble6, Adam W. Glaser5,7,
Richard G. Grundy6,8, Lennard Y. W. Lee 9, Martin G. McCabe10,11, Robert S. Phillips12,13, Charles A. Stiller11, Csilla Várnai3,14 and
Pamela R. Kearns2,15
BACKGROUND: Children with cancer are frequently immunocompromised. While children are generally thought to be at less risk of
severe SARS-CoV-2 infection than adults, comprehensive population-based evidence for the risk in children with cancer is
unavailable. We aimed to produce evidence of the incidence and outcomes from SARS-CoV-2 in children with cancer attending all
hospitals treating this population across the UK.
METHODS: Retrospective and prospective observational study of all children in the UK under 16 diagnosed with cancer through
data collection from all hospitals providing cancer care to this population. Eligible patients tested positive for SARS-CoV-2 on
reverse transcription polymerase chain reaction (RT-PCR). The primary end-point was death, discharge or end of active care for
COVID-19 for those remaining in hospital.
RESULTS: Between 12 March 2020 and 31 July 2020, 54 cases were identified: 15 (28%) were asymptomatic, 34 (63%) had mild
infections and 5 (10%) moderate, severe or critical infections. No patients died and only three patients required intensive care
support due to COVID-19. Estimated incidence of hospital identified SARS-CoV-2 infection in children with cancer under 16 was 3%.
CONCLUSIONS: Children with cancer with SARS-CoV-2 infection do not appear at increased risk of severe infection compared to
the general paediatric population. This is reassuring and supports the continued delivery of standard treatment.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01181-0
BACKGROUND
Intensive treatment of children with cancer delivered by robust
networks of national and international clinical trial consortia has
led to marked improvements in survival over the last four
decades.1 Therapy frequently results in significantly compromised
immunity with infection being a major cause of mortality.2–6 Data
from China, corroborated by other countries, suggest that adults
with cancer are more at risk of contracting SARS-CoV-2 than the
general population and are more likely to suffer from a severe
form of the COVID-19 illness.7–10 Other datasets have shown that
in a non-immunocompromised population, children are less
severely affected if they contract SARS-CoV-2 than adults.11,12
While the impact of SARS-CoV-2 in this population is yet to be
defined, the international paediatric oncology community has
acted at pace to provide guidance and support to childhood
cancer patients to minimise their risk of infection during the
pandemic.13,14 However, the emerging evidence base for this is
understandably limited with data restricted to individual case
reports or series from single institutions as well as some
incomplete regional or national datasets.15–18
To characterise the effects of COVID-19 in children with cancer
who have attended hospital on a population-wide basis, the
network of specialist hospitals managing children with cancer
across the United Kingdom (UK) and the Children’s Cancer and
Leukaemia Group (CCLG) established the UK Paediatric Coronavirus
Cancer Monitoring Project (https://ukcoronaviruscancermonitoring.
com/paediatrics/), based on the same platform as the UK
Coronavirus Cancer Monitoring Project that recently reported data
www.nature.com/bjc
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on adult cancer.19,20 We present the initial data from this project up
to the end of July 2020, spanning the initial peak of the COVID-19
pandemic in the UK
METHODS
All children and adolescents under the age of 16 years with cancer
in the UK are managed by one of 20 Principal Treatment Centres
(PTCs). All PTCs are represented within an umbrella organisation—
the Children’s Cancer and Leukaemia Group (CCLG). All twenty
PTCs in the UK were invited to participate in the study (the single
CCLG-affiliated centre outside the UK was excluded). The project
was launched on 7 April 2020 with the facility for both prospective
and retrospective data collection. Data were collected up to and
including the 31 July 2020.
All SARS-CoV-2-positive cases were identified by confirming the
presence of viral RNA in respiratory swabs by reverse transcription
polymerase chain reaction (RT-PCR), according to the appropriate
national public health guidance. RT-PCR was not mandated by the
protocol.
The UK Paediatric Coronavirus Cancer Monitoring Project
database was designed as a public health surveillance registry
to support rapid clinical decision making, in accordance with the
UK Policy Framework for Health and Social Care Research, the UK
National Research Ethics Service, and the UK Governance
Arrangement for Research Ethic Committees. At an institutional
level, this cohort study was approved according to local
information governance processes.
Each participating centre had a designated local Emergency
Response Reporting Individual (ERRI) who was responsible for data
collection at a local level and was supported by a Local Emergency
Response Reporting Group (LERRG). All information was de-
identified at source to ensure strict anonymity when shared with
the research team. Data were submitted via the research
electronic data capture (REDCap) database that is browser based
and metadata derived.21 REDCap is hosted by the Institute of
Translational Medicine at the University of Birmingham, Birming-
ham, UK.22
Data were collected on age, sex, ethnicity, presentation with
COVID-19, severity of COVID-19 (Table 1), type of malignancy and
treatment to date as well as clinical outcomes including survival
and need for ongoing hospital-based care.
Initial contact was made with the ERRI at each centre by the
Steering Committee to encourage reporting of cases and
completeness of datasets. This was followed with two subsequent
email communications. Some care of childhood cancer patients
in the UK is provided by general paediatricians in Paediatric
Oncology Shared Care Units (POSCUs) under the oversight of a
PTC. POSCU clinicians were given access to submit data,
which was linked to their PTC, so that patients testing positive
for SARS-CoV-2 at a POSCU were captured while ensuring that
data were not duplicated.
Paediatric patients who had received an allogeneic stem cell
transplant were excluded as this data were being separately
collected by the European Society for Blood and Marrow
Transplantation as part of their study looking at SARS-CoV-2 in
post-transplant patients (https://www.ebmt.org/covid-19-and-
bmt).
Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation or writing of the
report. GM had full access to all data from the study and had the
final responsibility for the decision to submit for publication.
RESULTS
Up to 31 July 2020, 54 children under the age of 16 years at the
time of testing were identified to have SARS-CoV-2 by PCR-based
testing and had complete datasets submitted. At the time of
reporting, the median observation time from positive SARS-CoV-2
test was 116 days (range 1–156 days). 98% of all patients have a
minimum of 4 weeks of follow-up data from their initial positive
test result.
Demographics of the patients are shown in Table 2. There was a
near equal sex ratio (29 boys:25 girls). The median age at positive
SARS-CoV-2 test was 5 years 0 months (range 10 months to 15
years, 9 months).
The most common cancer diagnostic group was acute
leukaemia; 44% of all patients had a diagnosis of acute
lymphoblastic leukaemia (ALL). 52% of all girls in the study had
ALL versus 38% of boys.
Thirty-three percent of children/young people with cancer
identified as having SARS-CoV-2 in the UK were from a black or
minority ethnic background (BAME).
Presentation with COVID-19
The overwhelming majority of patients had mild or asymptomatic
infections with SARS-CoV-2 (Fig. 1). Eighty-seven percent of all
symptomatic patients presented with fever while 62% had either
cough or coryzal symptoms at presentation. Ten percent of
patients had GI symptoms at presentation.
Only five patients had more than asymptomatic/mild infection
(one moderate, one severe and three critical). All of these
patients were aged under 10 and had diagnoses of ALL (n= 2,
including one relapse), hepatoblastoma (one), osteosarcoma
(one) and neuroblastoma (one). Three patients required
intensive care support including one who had a background
of chronic lung disease. All five patients recovered from their
SARS-CoV-2 infection and were either discharged from hospital
Table 1. Coronavirus severity index.
Asymptomatic Asymptomatic but positive diagnostic test (undertaken for other reasons).
Mild Symptoms of acute upper respiratory tract infection, including fever, fatigue, myalgia, cough, sore throat, runny nose and sneezing.
Clear chest on auscultation. Some cases may have no fever, or have only digestive symptoms such as nausea, vomiting, abdominal
pain and diarrhoea.
Moderate Signs of pneumonia including fever, cough and crepitations. No increased work of breathing.
Some cases may have no clinical signs and symptoms, but chest CT shows lung lesions, which are subclinical.
Severe Respiratory distress—respiratory rate ≥70 breaths per min for infants aged <1 year, ≥50 breaths per min for children >1 year. Oxygen
saturation less than 92%. Dehydration requiring intravenous fluid support.
Critical Acute respiratory distress syndrome (ARDS) or respiratory failure requiring ventilator support. Signs of shock, encephalopathy,
myocardial injury or heart failure, coagulation dysfunction or acute kidney injury. Need for ICU support for other reasons.
Adapted from Dong et al. and Qiu et al.11,12
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or remain in secondary care for reasons unrelated to the
infection.
Admission to hospital
The majority of patients were not admitted to hospital specifically
for their SARS-CoV-2 infection based on the clinical review of the
local team (see Fig. 2). Of those who were admitted for non-SARS-
CoV-2 reasons, the majority had a fever and were initially admitted
for intravenous antibiotics while awaiting the outcome of a febrile
neutropenia screen. It is also common practice in some PTCs in the
UK for children who present with non-neutropenic fever and are
clinically well to be treated as outpatients with oral antibiotics,
reducing the need for hospital admission.
Treatment received
Treatment data were available for 38/54 patients (70%). Of those
with available data, 21% were receiving very myelosuppressive
chemotherapy (either induction/delayed intensification che-
motherapy for ALL or chemotherapy for AML). Twenty-nine
percent of patients were receiving less intensive chemotherapy
(either maintenance chemotherapy for ALL/RMS or weekly
vincristine). The remaining 50% of patients were receiving a
range of other more standard chemotherapy regimens. Twenty-six
percent of patients were receiving targeted or immune therapy
with or without conventional chemotherapy including dinutux-
imab beta, inotuzumab ozogamicin, blinatumomab, gemtuzomab
ozogamicin and larotrectinib. No patients had received high dose
chemotherapy or autologous stem cell support within the 28 days
preceding their positive SARS-CoV-2 result.
Of those patients with moderate, severe or critical infections,
one was receiving relapse treatment, one was having delayed
intensification, two were having other chemotherapy and one was
having targeted therapy with blinatumomab.
Outcome data
The majority of patients (46 (85%)) did not require admission to
hospital or were admitted for a period of time and subsequently
discharged following their diagnosis with COVID-19. Seven (13%)
patients remained in hospital for reasons unrelated to their
COVID-19. Only one patient (2%) died who was on a palliative
pathway prior to the onset of COVID-19. Cause of death was
progressive disease rather than from COVID-19.
DISCUSSION
To the best of our knowledge, the UK Paediatric Coronavirus
Cancer Monitoring Project is the first national hospital whole
population-based registry of paediatric patients with cancer with
confirmed SARS-CoV-2 to be reported internationally.
Our data have a similar spectrum of severity to those published
from a case series of children from across China with COVID-19
reported to the Chinese Centre for Disease Control and Prevention
in January and February 2020 and is in keeping with the reporting
emerging from other countries. The Chinese report showed that
5.6% patients had either severe or critical illness, which compared
to 6.6% in our data and 8% in a recent pan-European study of
COVID-19 in children. The results suggest that children and young
people with cancer who contract COVID-19 are not at any
more risk of serious infection than children in the general
population.12,15–18,23 However, it is worth noting the low incidence
in this population overall which may be related to the strict
implementation of stringent shielding advice at the beginning of












Acute lymphoblastic leukaemia 24 44.4
Acute myeloid leukaemia 4 7.4
CNS tumour 5 9.3
Neuroblastoma 6 11.1
Sarcomas 4 7.4
Wilms tumour 2 3.7
Hepatoblastoma 2 3.7
Retinoblastoma 2 3.7
Hodgkin lymphoma 1 1.9
Burkitt lymphoma 1 1.9
Others/non-malignant 3 5.6
Total patients 54 100
Sarcoma subtypes—1 × rhabdomyosarcoma, 2 × osteosarcoma, 1 × soft
tissue sarcoma. Other tumours—1 × kaposiform haemangioendothelioma,










Asymptomatic Mild Moderate Severe Critical
Severity index
Fig. 1 Severity index of patients presenting with SARS-CoV-2
infection. Each bar shows the absolute number of patients with
















Fig. 2 Requirement for admission to hospital for patients with
SARS-CoV-2 infection. Each bar represents the need for admission
to hospital and the relationship between this and SARS-CoV-2
decided by the local team.
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the outbreak due to the uncertainty about the severity of the
infection in immunocompromised children.
Data released by Public Health England show that approxi-
mately 1460 children with cancer aged under 16 years at
diagnosis are treated with systemic anticancer therapy each
week in England.24 Extrapolating these data, we estimate that
UK-wide there are currently ~1700 children under the age of 16
years in the UK undergoing chemotherapy treatment for cancer
on any week in time. Since the first report of SARS-CoV-2 in the
UK, we have collected data on 54 childhood cancer patients. As
all PTCs across the UK participated in the study and we verified
that all patients attending hospital who were SARS-CoV-2
positive were included, therefore our cohort approximates to
3% of the population of childhood cancer patients receiving
systemic anticancer therapy per week. This is similar to that
reported from a large hospital in Madrid.17 ALL accounted for
44% of children in this study, compared with around one quarter
of all childhood cancer incidence, but the duration of treatment
for ALL is considerably longer than for most other childhood
malignancies and therefore we would anticipate proportionately
there would be more children with ALL on treatment in a fixed
time-period.
The median time between positive test for SARS-CoV-2 and the
data cut-off date of 31 July is 116 days. We believe that it is
therefore unlikely that the outcome from infection for any patient
within our cohort will now change.
We had a similar ratio of girls to boys reported in our study
with a small male excess. This is similar to the series reported by
the Chinese Centre for Disease Control and Prevention, in which
there was no significant difference in rate of COVID-19 between
boys and girls.12 Our data are in stark contrast to the report from
Memorial Sloan Kettering demonstrating 85% of all patients
with a positive result were boys.25 It is difficult to explain the
marked discrepancy; however, our results are much closer to
the UK incidence figures for children with cancer, which show a
small male excess.26
The incidence of SARS-CoV-2 infection in children from black
and minority ethnic populations in our study is in keeping with
the general literature, which suggests that there may be an
increased infection risk for these individuals. The most recent
published ethnicity data for children with cancer in the UK had
an incidence of 9% in children from BAME backgrounds.27 The
numbers of SARS-CoV-2 cases we have reported are small and
the ethnicity data are incomplete. In addition, the most recent
published incidence data for ethnicity in children with cancer is
more than 12 years old and the demographics of the wider
population may have changed in that time. However, our
ethnicity finding is in keeping with that reported in other
populations of a higher incidence of SARS-CoV-2 infection in
non-white individuals.28,29
Figure 2 details the requirement for admission to hospital,
which was decided by the treating oncology team. The local
oncology team did not ascribe COVID-19 as the reason for
admission in 16 out of 54 patients. In four cases, the admission
was routine and the COVID-19 swab was identified as part of an
asymptomatic screening process. However, 75% (12 out of 16)
had an isolated fever on admission. These patients with an
isolated fever were admitted to be monitored for signs of
serious bacterial infections and, when deemed clinically fit for
discharge, were allowed to go home, in accordance with routine
practice for children with a fever on chemotherapy. While the
admitting team did not ascribe the fever to COVID-19, it is
clearly a recognised symptom. It is possible that some patients
were incorrectly coded as requiring admission to hospital, which
was unrelated to SARS-CoV-2; however, none of this cohort
developed severe symptoms or required ICU support. Even if
the fever in these patients was COVID-19 related, this is still
consistent with the conclusion that children with cancer who
contract COVID-19 are not at more risk of severe infection than
the general population.
The patients in our dataset had a range of chemotherapy
treatments in the 4 weeks preceding their SARS-CoV-2 infection
including more intensive chemotherapy regimens such as
induction or delayed intensification regimens for ALL. Although
it is difficult to accurately define intensity of chemotherapy,
we observed no trend towards more serious infection in
those who received the more intensive types of therapy,
although the numbers are small so it is difficult to draw
definitive conclusions.
The most important strength of our study is that the
design, alongside the organisational structure of healthcare
delivery for children with cancer across the UK and the 100%
participation of PTCs means there is a high level of certainty of
comprehensive case ascertainment of SARS-CoV-2 infections
identified by hospitals across the UK in those aged under
16 years receiving systemic anticancer therapy for malignancy.
There will be an underestimation of the proportion of
patients under 16 years of age with cancer who have contracted
SARS-CoV-2 who have been asymptomatic or, at most, suffered
mild symptoms. However, carers of children with cancer are
well educated in the need to contact their PTC or POSCU if their
child develops any symptoms. Consequently, we would expect
all patients on active treatment who were more severely
affected to have been reviewed in hospital and tested for
SARS-CoV-2.
One limitation of our study is that, for the duration of the study,
there has not been a uniform testing policy across the UK. At the
beginning of the data collection period, only patients with
symptoms consistent with SARS-CoV-2 who required admission
to hospital were being routinely tested. Over the course of the
study, this has changed so that all patients requiring admission to
hospital for any reason are tested as well as those who require
elective surgical procedures. These changes will have happened at
different time points in different PTCs around the UK and at
different points in the devolved nations. Although this study was
carried out across all UK paediatric oncology centres, the number
of positive patients is still small. The study is therefore prone to
potential selection bias, exacerbated by small numbers and the
changing policy on testing individuals throughout the study
period.
Another possible limitation relates to the test for diagnosis of
SARS-CoV-2 infection. In our study, all patients were diagnosed
with a positive RT-PCR result from a combined nose/throat swab.
There have been well documented concerns about the accuracy
of this form of test, particularly regarding the sensitivity.30 In
addition, the indication for performing a test which was based on
national public health advice has changed frequently through the
course of the study. These factors likely combine to mean that
there is a greater proportion of children with cancer in the
population who have been infected with SARS-CoV-2 but have
either not been unwell enough to present to hospital or have had
a negative PCR.
While this paper focuses on the risks to children and
adolescents with cancer who develop proven SARS-CoV-2
infection rather than the risk of being infected, the results have
informed precautionary advice given to healthcare professionals
and parents. The initial advice was highly protective of those
thought to be at high risk due to their immunocompromised
status. The data presented here are reassuring that children with
cancer are at no greater risk of severe disease than the general
paediatric population and is in keeping with emerging Interna-
tional data. Consequently, national bodies have been able to
ease some of the more stringent recommendations for patients
in this population.31
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CONCLUSION
We present data from the first published national population
registry of paediatric oncology patients attending hospital with
SARS-CoV-2 infection. Although numbers are small, the data
suggest that this group of patients are not at high risk of severe
infections, similar to what has been observed in children in the
wider population. These population-based data confirm the initial
reports released early in the pandemic. It provides further
evidence of the importance of continuing to provide routine
cancer care to children and young people with malignancies in
the time of COVID-19 and provides a model for how future
registries could be developed for rapidly evolving conditions in
populations affected by rare diseases.
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